Deccan Health Care Reports Robust Q2 Growth: Revenue Surges 29.7%, Profit Jumps 67.5%

Deccan Health Care has reported strong financial performance for the second quarter, demonstrating significant growth in both revenue and profitability.

Financial Highlights

Metric	Q2 FY2025-26	YoY Growth
Revenue	₹2,440.46 lakh	29.7%
Net Profit	₹89.97 lakh	67.5%
EBITDA Margin	7.0%	Up from 3.4%

The company's standalone revenue for Q2 reached ₹2,440.46 lakh, marking a substantial 29.7% increase year-over-year. This growth was primarily driven by product diversification and digital expansion strategies. The net profit for the quarter stood at ₹89.97 lakh, representing a remarkable 67.5% surge compared to the same period last year.

Improved Profitability

Deccan Health Care has significantly enhanced its profitability, with the EBITDA margin improving to 7.0% from 3.4% in the previous year. This improvement reflects the company's focus on operational efficiency and cost management.

Half-Year Performance

For the first half of FY2025-26, Deccan Health Care reported:

Standalone revenue of ₹4,587.41 lakh, up 35.4% YoY
Half-yearly PAT of ₹111.22 lakh, an increase of 22.8% YoY

Strategic Initiatives

The company has broadened its wellness portfolio with innovative product launches, including:

EnergyDecc™
SlimDecc™
Reactive Go Advanced
New range of functional fruit bars and gummies

Deccan Health Care has also introduced a Weight Wellness Program, focusing on metabolic balance, vitality, and holistic well-being through three synergistic formulations.

Global Expansion

The company is actively pursuing international growth:

Regulatory approvals filed in 6 international markets
Product launches in UAE and GCC planned for March 2026

Management Commentary

Mr. Mohak from Deccan Health Care stated, "Our Q2 performance demonstrates the resilience of our model and rising consumer preference for preventive, scientific wellness. We remain focused on disciplined execution, export-readiness, and sustained long-term value creation."

Outlook

With its strong financial performance, product innovation, and international expansion plans, Deccan Health Care appears well-positioned for continued growth in the preventive healthcare and wellness sector. The company's focus on science-backed formulations and strategic market expansion may contribute to its future success in both domestic and international markets.

Investors and stakeholders will likely keep a close eye on Deccan Health Care's ability to maintain this growth trajectory and successfully execute its expansion plans in the coming quarters.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-0.24%	+3.88%	+10.47%	-13.95%	-39.69%	-50.68%

Deccan Health Care Limited has announced the reappointment of Ruchi Khattar as an Independent Director in the Non-Executive category. This decision, approved by shareholders at the company's 29th Annual General Meeting, extends Khattar's tenure for a second term of five years, from September 4, 2025, to September 3, 2030.

Reappointment Details

The reappointment was based on the recommendation of the Nomination and Remuneration Committee and received shareholder approval. Khattar, who holds the Director Identification Number (DIN) 01966349, will continue to serve on the board in a non-executive capacity.

Professional Background

Ruchi Khattar brings a wealth of experience to her role at Deccan Health Care:

Education: Graduate from Lady Sri Ram College, Delhi University
Experience: 25 years in accounts, finance, and insurance compliance
Previous Roles: Senior Member at Max Bupa Health Insurance Company Limited and Max Insurance Company Limited

Corporate Governance

The company has affirmed that Khattar is not related to any other directors of Deccan Health Care Limited. Furthermore, it has been disclosed that she is not debarred from holding a directorship by any regulatory authority, ensuring compliance with corporate governance standards.

About Deccan Health Care Limited

Deccan Health Care Limited, with its registered office in Hyderabad, Telangana, operates in the healthcare sector. The company, established in 1996, is listed on the BSE and holds the Corporate Identification Number (CIN) L72200TG1996PLC024351.

This reappointment underscores the company's commitment to maintaining experienced leadership on its board of directors, potentially contributing to its strategic direction and governance in the coming years.